Treatment with galcanezumab in patients with episodic and chronic migraine does not result in an increased risk of CV events.
Researchers argue that chronic migraine should not be solely defined by headache frequency alone.
Production and distribution of Excedrin Extra Strength and Excedrin Migraine products have been temporarily stopped, maker GlaxoSmithKline said Tuesday.
Survey findings suggest that cluster headache attacks can negatively affect an individual’s career, education, and social life.
Acute treatment of migraine with ubrogepant, an oral calcitonin gene-related peptide antagonist, was superior to placebo for migraine pain freedom.
The newly developed Migraine Aura Complexity Score is effective for stratifying patients with migraine with aura.
Researchers found that a poor night’s sleep may increase risk for migraine the following day, rather than the next morning.
The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults.
Evidence supports the use of high-dose aspirin for treating acute migraine and low-dose aspirin for prevention of recurrent attacks.
Various migraine subgroups based on comorbidities can predict the risk for the progression of episodic migraine to chronic migraine.